Published in Women's Health Weekly, April 19th, 2001
Faslodex is characterized as an estrogen receptor downregulator and works differently than other hormonal breast cancer drugs in that it targets and degrades the estrogen receptor. Currently, advanced breast cancer patients whose tumors have been shown to use hormones to grow, are given drugs like tamoxifen that act by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly